Abbott Laboratories (ABT) financial statements: income statement, balance sheet and cash flow
Abbott Laboratories's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Abbott Laboratories reported revenue of $44.3B (+5.7% year on year) and net income of $6.5B (-51.3% year on year).
Income statement
Abbott Laboratories income statement, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Net Sales
$44.3B
$42.0B
$40.1B
$43.7B
Cost of products sold, excluding amortization of intangible assets
$19.3B
$18.7B
$18.0B
$19.1B
Amortization of intangible assets
$1.7B
$1.9B
$2.0B
$2.0B
Research and development
$2.9B
$2.8B
$2.7B
$2.9B
Selling, general and administrative
$12.3B
$11.7B
$10.9B
$11.2B
Total Operating Cost and Expenses
$36.3B
$35.1B
$33.6B
$35.3B
Operating Earnings
$8.1B
$6.8B
$6.5B
$8.4B
Interest expense
$493.0M
$559.0M
$637.0M
$558.0M
Interest income
($308.0M)
($344.0M)
($385.0M)
($183.0M)
Net foreign exchange (gain) loss
($50.0M)
($27.0M)
$41.0M
$2.0M
Other (income) expense, net
($548.0M)
($376.0M)
($479.0M)
($321.0M)
Earnings before Taxes
$8.5B
$7.0B
$6.7B
$8.3B
Taxes on Earnings
$1.9B
($6.4B)
$941.0M
$1.4B
Net Earnings
$6.5B
$13.4B
$5.7B
$6.9B
Basic Earnings Per Common Share (in dollars per share)
$3.73
$7.67
$3.28
$3.94
Diluted Earnings Per Common Share (in dollars per share)
$3.72
$7.64
$3.26
$3.91
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)
1.7B
1.7B
1.7B
1.8B
Dilutive Common Stock Options (in shares)
7.0M
8.0M
9.0M
11.0M
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)
1.7B
1.7B
1.7B
1.8B
Outstanding Common Stock Options Having No Dilutive Effect (in shares)
$1000000.00
$7000000.00
$5000000.00
$3000000.00
Abbott Laboratories income statement, quarters
Line item
Jun 30, 2026 · Q2
Mar 31, 2026 · Q1
Sep 30, 2025 · Q3
Jun 30, 2025 · Q2
Net sales
$12.6B
$11.2B
$11.4B
$11.1B
Cost of products sold, excluding amortization of intangible assets
$5.3B
$4.9B
$5.1B
$4.9B
Amortization of intangible assets
$658.0M
$422.0M
$420.0M
$420.0M
Research and development
$892.0M
$767.0M
$766.0M
$725.0M
Selling, general, and administrative
$4.0B
$3.7B
$3.1B
$3.1B
Total operating cost and expenses
$10.9B
$9.8B
$9.3B
$9.1B
Operating earnings
$1.7B
$1.3B
$2.1B
$2.1B
Interest expense
$351.0M
$174.0M
$121.0M
$121.0M
Interest (income)
($52.0M)
($106.0M)
($77.0M)
($71.0M)
Net foreign exchange (gain) loss
$4.0M
($13.0M)
($17.0M)
($11.0M)
Other (income) expense, net
($134.0M)
($159.0M)
($150.0M)
($137.0M)
Earnings before taxes
$1.5B
$1.4B
$2.2B
$2.1B
Taxes on earnings
$596.0M
$372.0M
$536.0M
$371.0M
Net Earnings
$928.0M
$1.1B
$1.6B
$1.8B
Basic Earnings Per Common Share (in dollars per share)
$0.53
$0.62
$0.94
$1.02
Diluted Earnings Per Common Share (in dollars per share)
$0.53
$0.61
$0.94
$1.01
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)
1.7B
1.7B
1.7B
1.7B
Dilutive Common Stock Options (in shares)
2.6M
4.6M
7.2M
7.4M
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)
1.7B
1.7B
1.7B
1.8B
Outstanding Common Stock Options Having No Dilutive Effect (in shares)
$11873000.00
$9900000.00
$1443000.00
$1442000.00
Balance sheet
Abbott Laboratories balance sheet, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Cash and cash equivalents
$8.5B
$7.6B
$6.9B
$9.9B
Investments, primarily bank time deposits and U.S. treasury bills
$417.0M
$351.0M
$383.0M
$288.0M
Trade receivables, less allowances of — 2025: $490; 2024: $439
$7.9B
$6.9B
$6.6B
$6.2B
Finished products
$4.0B
$3.7B
$3.9B
$3.8B
Work in process
$904.0M
$840.0M
$807.0M
$680.0M
Materials
$1.6B
$1.7B
$1.8B
$1.7B
Total inventories
$6.5B
$6.2B
$6.6B
$6.2B
Other prepaid expenses and receivables
$2.6B
$2.6B
$2.3B
$2.7B
Total current assets
$26.0B
$23.7B
$22.7B
$25.2B
Investments
$918.0M
$886.0M
$799.0M
$766.0M
Land
$541.0M
$528.0M
$529.0M
$511.0M
Buildings
$4.5B
$4.2B
$4.2B
$4.1B
Equipment
$17.6B
$15.5B
$15.2B
$14.2B
Construction in progress
$2.6B
$2.5B
$2.1B
$1.5B
Property and equipment, at cost
$25.2B
$22.7B
$21.9B
$20.2B
Less: accumulated depreciation and amortization
$13.4B
$12.1B
$11.8B
$11.1B
Net property and equipment
$11.8B
$10.7B
$10.2B
$9.2B
Intangible assets, net of amortization
$5.5B
$6.6B
$8.8B
$10.5B
Goodwill
$24.0B
$23.1B
$23.7B
$22.8B
Deferred income taxes and other assets
$18.4B
$16.5B
$7.1B
$6.0B
Total Assets
$86.7B
$81.4B
$73.2B
$74.4B
Trade accounts payable
$4.2B
$4.2B
$4.3B
$4.6B
Salaries, wages, and commissions
$1.7B
$1.7B
$1.6B
$1.6B
Other accrued liabilities
$5.8B
$5.1B
$5.4B
$5.8B
Dividends payable
$1.1B
$1.0B
$955.0M
$887.0M
Income taxes payable
$569.0M
$594.0M
$492.0M
$343.0M
Current portion of long-term debt
$3.0B
$1.5B
$1.1B
$2.3B
Total current liabilities
$16.5B
$14.2B
$13.8B
$15.5B
Long-term debt
$9.9B
$12.6B
$13.6B
$14.5B
Post-employment obligations and other long-term liabilities
$7.5B
$6.7B
$6.9B
$7.5B
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued
0
0
0
0
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2025: 1,996,795,525; 2024: 1,991,472,630
25.5B
25.2B
24.9B
24.7B
Common shares held in treasury, at cost — Shares: 2025: 260,196,074; 2024: 259,774,639
-17.2B
-16.8B
-16.0B
-15.2B
Earnings employed in the business
$49.8B
$47.3B
$37.6B
$35.3B
Accumulated other comprehensive income (loss)
($6.0B)
($7.9B)
($7.8B)
($8.1B)
Total Abbott Shareholders’ Investment
$52.1B
$47.7B
$38.6B
$36.7B
Noncontrolling interests in subsidiaries
$641.0M
$237.0M
$224.0M
$219.0M
Total Shareholders’ Investment
$52.8B
$47.9B
$38.8B
$36.9B
Total Liabilities and Shareholders' Investment
$86.7B
$81.4B
$73.2B
$74.4B
Abbott Laboratories balance sheet, quarters
Line item
Jun 30, 2026
Mar 31, 2026
Sep 30, 2025
Jun 30, 2025
Cash and cash equivalents
$5.1B
$6.8B
$7.5B
$7.0B
Short-term investments
$499.0M
$492.0M
$222.0M
$331.0M
Trade receivables, less allowances of $486 in 2026 and $490 in 2025
$8.6B
$8.2B
$8.1B
$8.0B
Finished products
$4.5B
$4.3B
$4.1B
$4.3B
Work in process
$1.0B
$994.0M
$961.0M
$962.0M
Materials
$1.8B
$1.7B
$1.6B
$1.7B
Total inventories
$7.3B
$7.0B
$6.7B
$7.0B
Prepaid expenses and other receivables
$3.0B
$3.0B
$2.3B
$2.3B
Total Current Assets
$24.5B
$25.5B
$24.8B
$24.5B
Investments
$1.1B
$1.1B
$951.0M
$958.0M
Property and equipment, at cost
$26.5B
$25.7B
$24.8B
$24.5B
Less: accumulated depreciation and amortization
$13.7B
$13.4B
$13.3B
$13.1B
Net property and equipment
$12.8B
$12.4B
$11.5B
$11.4B
Intangible assets, net of amortization
$17.2B
$17.9B
$5.6B
$5.9B
Goodwill
$35.2B
$35.2B
$24.0B
$24.0B
Deferred income taxes and other assets
$18.3B
$18.4B
$17.3B
$17.3B
Total Assets
$109.2B
$110.4B
$84.2B
$84.0B
Trade accounts payable
$4.8B
$4.7B
$4.1B
$4.3B
Salaries, wages, and commissions
$1.6B
$1.2B
$1.7B
$1.6B
Other accrued liabilities
$6.9B
$6.4B
$5.9B
$5.7B
Dividends payable
$1.1B
$1.1B
$1.0B
$1.0B
Income taxes payable
$411.0M
$598.0M
$469.0M
$390.0M
Current portion of long-term debt
$3.0B
$4.4B
$1.3B
$507.0M
Total Current Liabilities
$17.8B
$18.4B
$14.6B
$13.4B
Long-term debt
$29.6B
$29.6B
$11.6B
$12.9B
Post-employment obligations, deferred income taxes, and other long-term liabilities
$10.0B
$9.7B
$6.7B
$6.8B
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued
0
0
0
0
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2026: 1,998,291,279; 2025: 1,996,795,525
25.5B
25.4B
25.4B
25.3B
Common shares held in treasury, at cost — Shares: 2026: 267,907,258; 2025: 260,196,074
-18.0B
-16.9B
-16.9B
-16.6B
Earnings employed in the business
$49.8B
$50.0B
$49.1B
$48.5B
Accumulated other comprehensive income (loss)
($6.2B)
($6.3B)
($6.7B)
($6.6B)
Total Abbott Shareholders’ Investment
$51.1B
$52.1B
$51.0B
$50.6B
Noncontrolling interests
$652.0M
$640.0M
$310.0M
$264.0M
Total Shareholders’ Investment
$51.8B
$52.7B
$51.3B
$50.8B
Total Liabilities and Shareholders' Investment
$109.2B
$110.4B
$84.2B
$84.0B
Cash flow statement
Abbott Laboratories cash flow statement, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Net earnings
$6.5B
$13.4B
$5.7B
$6.9B
Depreciation
$1.4B
$1.3B
$1.3B
$1.3B
Amortization of intangible assets
$1.7B
$1.9B
$2.0B
$2.0B
Share-based compensation
$664.0M
$673.0M
$644.0M
$685.0M
Investing and financing losses, net
$65.0M
$482.0M
$126.0M
$215.0M
Trade receivables
($652.0M)
($691.0M)
($356.0M)
($68.0M)
Inventories
$195.0M
($58.0M)
($232.0M)
($1.4B)
Prepaid expenses and other assets
($1.3B)
($796.0M)
($542.0M)
($75.0M)
Trade accounts payable and other liabilities
$954.0M
$356.0M
($760.0M)
$420.0M
Income taxes
($5.0M)
($8.0B)
($585.0M)
($383.0M)
Net Cash From Operating Activities
$9.6B
$8.6B
$7.3B
$9.6B
Acquisitions of property and equipment
($2.2B)
($2.2B)
($2.2B)
($1.8B)
Acquisitions of businesses and technologies, net of cash acquired
($105.0M)
$0
($877.0M)
$0
Proceeds from business dispositions
$0
$1.0M
$40.0M
$48.0M
Purchases of investment securities
($167.0M)
($169.0M)
($159.0M)
($185.0M)
Proceeds from sales of investment securities
$3.0M
$28.0M
$43.0M
$152.0M
Other
$18.0M
$9.0M
$22.0M
$22.0M
Net Cash From (Used in) Investing Activities
($2.4B)
($2.3B)
($3.1B)
($1.7B)
Proceeds from issuance of (repayments of) short-term debt, net and other
($115.0M)
($100.0M)
$21.0M
$47.0M
Proceeds from issuance of long-term debt and debt with maturities over 3 months
$5.0M
$223.0M
$2.0M
$7.0M
Repayments of long-term debt and debt with maturities over 3 months
($1.5B)
($660.0M)
($2.5B)
($753.0M)
Purchases of common shares
-893.0M
-1.3B
-1.2B
-3.8B
Proceeds from stock options exercised
$396.0M
$264.0M
$167.0M
$167.0M
Dividends paid
($4.1B)
($3.8B)
($3.6B)
($3.3B)
Other
($82.0M)
—
—
$0
Net Cash From (Used in) Financing Activities
($6.3B)
($5.4B)
($7.1B)
($7.6B)
Effect of exchange rate changes on cash and cash equivalents
$71.0M
($96.0M)
($23.0M)
($122.0M)
Net Increase (Decrease) in Cash and Cash Equivalents
$906.0M
$720.0M
($3.0B)
$83.0M
Cash and Cash Equivalents, Beginning of Year
$7.6B
$6.9B
$9.9B
$9.8B
Cash and Cash Equivalents, End of Year
$8.5B
$7.6B
$6.9B
$9.9B
Income taxes paid
$1.9B
$1.7B
$1.5B
$1.9B
Interest paid
$545.0M
$604.0M
$662.0M
$563.0M
Abbott Laboratories cash flow statement, quarters
Line item
Jun 30, 2026 · YTD
Mar 31, 2026 · Q1
Sep 30, 2025 · YTD
Jun 30, 2025 · YTD
Net earnings
$2.0B
$1.1B
$4.7B
$3.1B
Depreciation
$783.0M
$381.0M
$1.1B
$693.0M
Amortization of intangible assets
$1.1B
$422.0M
$1.3B
$840.0M
Share-based compensation
$485.0M
$317.0M
$551.0M
$431.0M
Trade receivables
($428.0M)
($42.0M)
($874.0M)
($672.0M)
Inventories
($721.0M)
($420.0M)
($39.0M)
($252.0M)
Other, net
$599.0M
($420.0M)
($459.0M)
($680.0M)
Net Cash From Operating Activities
$3.8B
$1.3B
$6.3B
$3.5B
Acquisitions of property and equipment
($896.0M)
($399.0M)
($1.5B)
($986.0M)
Acquisitions of businesses and technologies, net of cash acquired
($20.0B)
($19.8B)
($85.0M)
($30.0M)
Sales (purchases) of other investment securities, net
($187.0M)
($161.0M)
$46.0M
($44.0M)
Other
$48.0M
$34.0M
$12.0M
$8.0M
Net Cash From (Used in) Investing Activities
($21.0B)
($20.3B)
($1.5B)
($1.1B)
Net borrowings (repayments) of short-term debt and other
$95.0M
$31.0M
($44.0M)
($52.0M)
Proceeds from issuance of long-term debt
$19.8B
$19.9B
$3.0M
$3.0M
Repayments of long-term debt
($2.8B)
($1.4B)
($1.5B)
($1.0B)
Purchases of common shares
-1.2B
-180.0M
-591.0M
-286.0M
Proceeds from stock options exercised
$119.0M
$116.0M
$391.0M
$322.0M
Dividends paid
($2.2B)
($1.1B)
($3.1B)
($2.1B)
Other
$0
—
($82.0M)
($82.0M)
Net Cash From (Used in) Financing Activities
$13.8B
$17.3B
($4.9B)
($3.2B)
Effect of exchange rate changes on cash and cash equivalents
($19.0M)
($23.0M)
$65.0M
$75.0M
Net Increase (Decrease) in Cash and Cash Equivalents